Your browser is no longer supported. Please, upgrade your browser.
Settings
FPRX Five Prime Therapeutics, Inc. daily Stock Chart
FPRX [NASD]
Five Prime Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.49 Insider Own1.80% Shs Outstand37.68M Perf Week9.07%
Market Cap154.11M Forward P/E- EPS next Y-2.89 Insider Trans- Shs Float35.67M Perf Month-28.50%
Income-155.80M PEG- EPS next Q-0.95 Inst Own75.60% Short Float3.41% Perf Quarter-27.74%
Sales18.50M P/S8.33 EPS this Y23.10% Inst Trans0.09% Short Ratio3.51 Perf Half Y-67.04%
Book/sh5.92 P/B0.69 EPS next Y23.70% ROA-48.10% Target Price12.33 Perf Year-68.94%
Cash/sh5.68 P/C0.72 EPS next 5Y- ROE-62.10% 52W Range3.22 - 14.48 Perf YTD-56.02%
Dividend- P/FCF- EPS past 5Y4.60% ROI-55.10% 52W High-70.99% Beta2.51
Dividend %- Quick Ratio6.90 Sales past 5Y29.30% Gross Margin- 52W Low30.43% ATR0.36
Employees168 Current Ratio6.90 Sales Q/Q-56.60% Oper. Margin- RSI (14)42.37 Volatility8.42% 8.47%
OptionableYes Debt/Eq0.00 EPS Q/Q0.50% Profit Margin- Rel Volume0.46 Prev Close4.09
ShortableYes LT Debt/Eq0.00 EarningsNov 06 AMC Payout- Avg Volume346.28K Price4.20
Recom2.30 SMA20-4.66% SMA50-18.23% SMA200-50.79% Volume88,636 Change2.69%
Oct-01-19Downgrade Guggenheim Buy → Neutral
Jun-03-19Downgrade Wells Fargo Outperform → Market Perform
May-29-19Initiated ROTH Capital Neutral $10
Apr-12-19Resumed Guggenheim Buy $24
Sep-13-18Resumed Leerink Partners Outperform $24
Jun-28-18Initiated Raymond James Mkt Perform
Jun-15-18Initiated JP Morgan Neutral $19
May-18-18Initiated Wedbush Neutral
Nov-06-17Reiterated RBC Capital Mkts Outperform $41 → $50
Sep-15-17Initiated RBC Capital Mkts Outperform $41
Mar-02-17Initiated Instinet Buy $94
Oct-25-16Initiated Citigroup Buy
Jan-21-16Initiated Credit Suisse Outperform
Dec-04-15Resumed Wells Fargo Outperform
Oct-19-15Reiterated Oppenheimer Outperform $45 → $48
Jul-31-15Initiated Citigroup Buy
May-15-15Initiated Oppenheimer Outperform $45
Oct-11-19 04:04PM  Insiders Roundup: Facebook, American Defense Systems GuruFocus.com
08:14AM  The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout Benzinga
Oct-10-19 09:57PM  South San Francisco biotech to cut another 70 jobs, may sublease space American City Business Journals
04:01PM  Five Prime Announces Restructuring Business Wire
Oct-02-19 07:30AM  Looking for 1,600% Returns? Biotech Has No Shortage of Analyst Optimism Bloomberg +5.15%
Sep-30-19 03:01AM  Five Prime Therapeutics Presents Updated Data From the Phase 1a/1b Trial of FPA150 at the European Society for Medical Oncology 2019 Congress Business Wire -9.36%
Sep-20-19 09:59AM  Peninsula biotech CEO resigns in latest corner office switch American City Business Journals
Sep-19-19 04:05PM  Five Prime Therapeutics Announces Management Transition Business Wire
12:18PM  What Kind Of Shareholder Owns Most Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Stock? Simply Wall St.
Aug-22-19 07:45PM  Five Prime Therapeutics to Present at Upcoming Healthcare Conference Business Wire
Aug-15-19 10:16PM  Edited Transcript of FPRX earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-07-19 06:25PM  Five Prime Therapeutics (FPRX) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:05PM  Five Prime Therapeutics Reports Second Quarter 2019 Results Business Wire
Aug-01-19 03:06PM  Cancer-fighting Peninsula company postpones $92 million IPO American City Business Journals
Jun-25-19 11:56AM  Estimating The Fair Value Of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Simply Wall St.
Jun-24-19 04:05PM  Five Prime Therapeutics Appoints Lori Lyons-Williams to its Board of Directors Business Wire
01:28PM  Is Five Prime Therapeutics Inc (FPRX) A Good Stock To Buy? Insider Monkey
Jun-18-19 08:50AM  Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 9.2% in Session Zacks
Jun-09-19 03:05PM  Five Prime Therapeutics Announces the Departure of Dr. Sheila Gujrathi From its Board of Directors Business Wire
03:00PM  Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences Business Wire
Jun-01-19 09:01AM  Five Prime Therapeutics Presents Monotherapy Data From the Phase 1a/1b Trial of FPA150 in Patients With Advanced Solid Tumors at the 2019 ASCO Annual Meeting Business Wire
May-24-19 04:01PM  Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences Business Wire
May-17-19 12:45PM  Edited Transcript of FPRX earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-15-19 06:39PM  Five Prime Therapeutics Appoints Carol Schafer to its Board of Directors Business Wire
05:45PM  Five Prime Therapeutics Announces FPA150 Poster Presentation at the 2019 ASCO Annual Meeting Business Wire
May-09-19 11:23AM  Five Prime Therapeutics (FPRX) Q1 2019 Earnings Call Transcript Motley Fool -5.03%
May-08-19 06:45PM  Five Prime Therapeutics (FPRX) Reports Q1 Loss, Misses Revenue Estimates Zacks
05:39PM  Five Prime Therapeutics: 1Q Earnings Snapshot Associated Press
04:05PM  Five Prime Therapeutics Reports First Quarter 2019 Results Business Wire
May-01-19 10:33AM  Earnings Preview: Five Prime Therapeutics (FPRX) Q1 Earnings Expected to Decline Zacks
Apr-30-19 09:04AM  Can 'synthetic lethality' and deep experience propel this cancer-fighting biotech's $70M IPO? American City Business Journals -7.20%
Apr-17-19 07:56PM  Five Prime Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on May 8 Business Wire
01:27PM  What Should You Know About Five Prime Therapeutics, Inc.'s (NASDAQ:FPRX) Earnings Trajectory? Simply Wall St.
Mar-25-19 09:19AM  Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more American City Business Journals
Mar-20-19 02:09PM  Edited Transcript of FPRX earnings conference call or presentation 26-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-19-19 09:28AM  Will Five Prime Therapeutics Continue to Surge Higher? Zacks
Mar-11-19 06:00AM  Five Prime Has 5 Drugs in its Pipeline MoneyShow
Mar-05-19 06:05PM  Five Prime Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference Business Wire
Feb-26-19 09:47PM  Five Prime Therapeutics Inc (FPRX) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:05PM  Five Prime Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results Business Wire
Feb-20-19 08:05PM  Five Prime Therapeutics Doses First Patient in Phase 1b Trial of FPA150 Business Wire
Feb-07-19 04:05PM  Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26 Business Wire
Feb-04-19 05:05PM  Five Prime Therapeutics to Present at the Guggenheim Healthcare Talks Idea Forum Business Wire
Jan-30-19 11:45PM  Why are deep-pocketed biotechs cutting hundreds of jobs? American City Business Journals
Jan-28-19 09:37AM  MacroGenics Up on Lifting of Partial Hold on Cancer Candidate Zacks -8.42%
Jan-24-19 03:13AM  Five Prime Therapeutics, Inc. (FPRX) Shares March Higher, Can It Continue? Zacks
Jan-17-19 02:05PM  Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium Business Wire +5.98%
Jan-16-19 07:40AM  Consolidated Research: 2019 Summary Expectations for Southern, Exelon, PriceSmart, Five Prime Therapeutics, Digi International, and Voyager Therapeutics Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-15-19 05:08PM  Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line American City Business Journals +9.40%
04:05PM  Five Prime Announces Restructuring to Focus on Clinical Development and Later-Stage Research Priorities Business Wire
Jan-14-19 06:41PM  Five Prime Therapeutics Announces Two Poster Presentations at the 2019 Gastrointestinal Cancers Symposium Business Wire
Jan-13-19 03:50PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Dec-12-18 04:05PM  Five Prime Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Nov-29-18 04:05PM  Five Prime Therapeutics Announces Changes to its Board of Directors Business Wire
Nov-27-18 07:15AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Nov-20-18 04:05PM  Five Prime Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference Business Wire
01:52PM  Edited Transcript of FPRX earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-14-18 04:05PM  Five Prime Therapeutics Initiates Patient Dosing in a Phase 1 Clinical Trial of FPT155, a First-in-Class CD80 Fusion Protein Business Wire
Nov-12-18 10:21AM  Health Care Digest: A big Berkeley bio incubator, Apple's clinical trial help and more American City Business Journals
Nov-09-18 08:40AM  New Research Coverage Highlights American Public Education, Protagonist Therapeutics, TravelCenters of America, Five Prime Therapeutics, Red Robin Gourmet Burgers, and Hemisphere Media Group Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-06-18 06:15PM  Five Prime Therapeutics (FPRX) Reports Q3 Loss, Misses Revenue Estimates Zacks
05:09PM  Five Prime Therapeutics: 3Q Earnings Snapshot Associated Press
04:05PM  Five Prime Therapeutics Announces Third Quarter 2018 Financial Results Business Wire
Nov-05-18 10:36AM  Five Prime Therapeutics Announces David V. Smith Will Join as Chief Financial Officer Business Wire
Nov-01-18 10:23AM  Big pharma leases almost 500,000 square feet for new research center American City Business Journals +7.00%
Oct-23-18 04:05PM  Five Prime Therapeutics to Announce Third Quarter 2018 Financial Results and Host Conference Call on November 6 Business Wire
Oct-16-18 09:00AM  Five Prime Therapeutics Initiates Patient Dosing in The Dose Exploration Cohort of Its Phase 1 Trial of Novel First-in-Class B7-H4 Antibody FPA150 Business Wire +6.18%
Oct-10-18 02:42PM  Consolidated Research: 2018 Summary Expectations for Five Prime Therapeutics, National Health Investors, Starwood Property Trust, Inc., Biohaven Pharmaceutical Holding, Aclaris Therapeutics, and Mitek Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-01-18 08:00AM  Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers Business Wire
Sep-26-18 04:05PM  Five Prime Therapeutics to Present at Leerink Partners Roundtable Series: Rare Disease & Oncology Business Wire
Sep-10-18 09:00AM  Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers Business Wire
Aug-30-18 04:05PM  Five Prime Therapeutics to Present at 2018 Wells Fargo Healthcare Conference Business Wire
Aug-21-18 09:50PM  Edited Transcript of FPRX earnings conference call or presentation 8-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-18 07:20PM  Five Prime Therapeutics (FPRX) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:14PM  Five Prime Therapeutics: 2Q Earnings Snapshot Associated Press
04:05PM  Five Prime Therapeutics Announces Second Quarter 2018 Financial Results Business Wire
02:30PM  Five Prime Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 08:00AM  Factors of Influence in 2018, Key Indicators and Opportunity within Five Prime Therapeutics, Akorn, The Blackstone Group, Avaya, Tractor Supply, and CymaBay Therapeutics New Research Emphasizes Economic Growth GlobeNewswire
Jul-26-18 04:05PM  Five Prime Therapeutics to Announce Second Quarter 2018 Financial Results and Host Conference Call on August 8 Business Wire
Jul-11-18 07:35AM  Complimentary Technical Snapshots on Incyte and Three More Biotech Stocks ACCESSWIRE
Jun-21-18 06:00AM  Five Prime Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Jun-11-18 04:05PM  Five Prime Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference Business Wire
Jun-07-18 11:05AM  5 Top-Ranked High-Beta Stocks to Play the Roaring Market InvestorPlace
Jun-03-18 09:00AM  Five Prime Therapeutics Presents Bemarituzumab Trial-in-Progress Poster at the 2018 ASCO Annual Meeting Business Wire
May-31-18 04:05PM  Five Prime Therapeutics to Present at Jefferies 2018 Global Healthcare Conference Business Wire
May-30-18 04:05PM  Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics for Targeted Immuno-Oncology Investigational Drug Candidates Business Wire
May-29-18 04:05PM  Five Prime Therapeutics Walks to End Pancreatic Cancer at PurpleStride San Francisco 2018 Business Wire
May-15-18 04:05PM  Five Prime Therapeutics Appoints Bryan Irving, Ph.D., as Chief Scientific Officer Business Wire
May-10-18 01:11AM  Edited Transcript of FPRX earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-08-18 06:09PM  Five Prime Therapeutics: 1Q Earnings Snapshot Associated Press -5.70%
04:05PM  Five Prime Therapeutics Announces First Quarter 2018 Financial Results Business Wire
Apr-25-18 03:01PM  Five Prime to Present at 2018 ASCO Annual Meeting Business Wire
Apr-24-18 04:05PM  Five Prime Therapeutics to Announce First Quarter 2018 Financial Results and Host Conference Call on May 8 Business Wire
Apr-15-18 02:50PM  Five Prime Presents on Novel B7-H4 Therapeutic Antibody at the 2018 AACR Annual Meeting Business Wire
Apr-03-18 02:07PM  Five Prime Therapeutics Inc (NASDAQ:FPRX): Poised For Long-Term Success? Simply Wall St.
07:00AM  Personal Genome Diagnostics Announces Collaboration to Develop Plasma-Based Companion Diagnostic for Five Prime Therapeutics' Targeted Immuno-Oncology Drug Candidate Bemarituzumab PR Newswire
Mar-28-18 04:05PM  Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Trial of Novel First-in-Class B7-H4 Antibody FPA150 Business Wire -5.96%
Mar-27-18 04:05PM  Five Prime Therapeutics Announces Oral Presentation on FPA150 at the 2018 AACR Annual Meeting Business Wire
Mar-22-18 09:16AM  5 Stocks that Boast Superb Earnings Acceleration Zacks
Mar-19-18 09:00AM  Five Prime Therapeutics Licenses New Target to UCB Originating from its Proprietary Protein Discovery Platform Business Wire
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; a collaboration agreement with Roche; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BVF PARTNERS L P/IL10% OwnerOct 08Buy3.6860,412222,4972,351,986Oct 08 05:40 PM
BVF PARTNERS L P/IL10% OwnerOct 07Buy3.75525,0701,968,6642,320,979Oct 08 05:40 PM
BVF PARTNERS L P/IL10% OwnerOct 04Buy3.7416,00059,8002,054,006Oct 08 05:40 PM
Knickerbocker Aron MarcPresident & CEOJun 07Option Exercise5.5411,35762,918195,828Jun 10 01:53 PM
Williams Lewis TExecutive ChairmanNov 05Option Exercise4.5691,217415,950465,430Nov 13 08:32 PM